ReviewAnnals of gastroenterological surgery2019
Cutting-edge strategies for borderline resectable pancreatic cancer.
Review in Annals of gastroenterological surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Review
- Article
- Evaluation of cryoablation using a prototype cryoablation needle in swine liver.Clinical endoscopy · 2024Article
- Oligo-like liver metastasis: A novel prognostic indicator to improve survival in pancreatic cancer.Annals of gastroenterological surgery · 2024Article
- Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer.Cell communication and signaling : CCS · 2024Article
- Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments.Frontiers in oncology · 2024Review
- Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma.Cancers · 2023Article
- Review
- Locoregional Therapies and Remodeling of Tumor Microenvironment in Pancreatic Cancer.International journal of molecular sciences · 2023Review
- The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.International journal of molecular sciences · 2023Review
- The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies.Biomedicines · 2021Review
- The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy.Frontiers in oncology · 2021Review
- Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma.Annals of gastroenterological surgery · 2021Review
- Cutting-edge strategies for borderline resectable pancreatic cancer.Annals of gastroenterological surgery · 2019Review
- Pancreatoduodenectomy En Bloc With Superior Mesenteric Artery Resection for Borderline Resectable Pancreatic Cancer - A Case Report and Literature Review.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, pancreatic ductal adenocarcinoma (PDAC) accounts for more than 400 000 deaths every year, being the 12th most common cancer and the seventh most frequent cause of death from cancer. Regardless of the advances in diagnosis and treatment, PDAC continues to have dismal outcomes and fewer than 25% of patients survive for 1 year. In the absence of metastatic disease, radical surgery remains the most important factor for improving survival and possibly offer cure. However, approximately 80% of patients cannot be offered surgery owing to locally advanced or metastatic disease at presentation. At presentation, only 10%-20% patients are eligible for resection, 30%-40% are unresectable/locally advanced and 50%-60% are metastatic. One promising development in recent years has been the inclusion of a new subgroup within the locally advanced tumors of borderline resectable pancreatic cancer (BRPC) comprising approximately 5%-10% of the total patient population. Although its exact definition has been refined over the past few years depending on the vascular involvement around the tumor, the term was initially proposed for tumors that are at a high risk of having margin positivity after resection. Various treatment approaches are still evolving for this entity. Herein, we reviewed the current status of different treatment modalities for BRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.